I agree. CYDY should give some explanation for the increase in AS. Honestly, I’m not too concerned about it, as leronlimab will have sales in 2020 and we will be far above .43, but what happens between now and then in terms of dilution is important to investors. If we will continue to see dilutive financing, well then, I’ll average down, but give us a clue as to what is going on, especially after saying a licensing deal is near.